Myelofibrosis

Imetelstat Active in Myelofibrosis, But May Cause Myelosuppression

Imetelstat Active in Myelofibrosis, But May Cause Myelosuppression

By

Imetelstat was active in patients with myelofibrosis, but had the potential to cause clinically significant myelosuppression.

Prior Myeloproliferative Neoplasm Associated with Poor Outlook for New Primary Cancers

Prior Myeloproliferative Neoplasm Associated with Poor Outlook for New Primary Cancers

By

Preceding myeloproliferative neoplasm is a predictor for poor outlook in patients who develop new primary cancers.

Pacritinib Reduces Spleen Volume in Patients with Myelofibrosis

Pacritinib Reduces Spleen Volume in Patients with Myelofibrosis

By

Pacritinib induced significant and sustained spleen volume reduction (SVR) and symptom control in patients with myelofibrosis.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs